Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (“Biota” or the “Company”), a biopharmaceutical company focused on the discovery and development of anti-infective products to prevent and treat serious and potentially life-threatening infectious diseases, today announced changes to its Board of Directors, including the resignation of Dr. Jeffrey Errington, and the appointment of Mr. John P. Richard to fill the vacancy created by Dr. Errington’s resignation.
AmpliPhi BioSciences Corp. (OTC: APHB) (“AmpliPhi”), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant bacterial infections, yesterday presented data relating to the use of bacteriophages in the treatment ofPseudomonas aeruginosa (P. aeruginosa) at the 20th Biennial Evergreen International Phage Meeting held inOlympia, Washington, USA. P. aeruginosa is the major cause of lung infections in cystic fibrosis (CF) patients.
The Australian government has approved a new, simplified Pharmaceutical Benefits Scheme (PBS) status for Bronchitol in the treatment of cystic fibrosis (CF).
Alchemia ASX announcements.
Avita Medical press release link here.
AmpliPhi BioSciences Corporation (OTC: APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage-based therapies to treat drug resistant bacterial infections, announced today a Collaborative Research and Development Agreement (CRADA) with the United States Army Medical Research and Materiel Command (USAMRMC) and the Walter Reed Army Institute of Research (WRAIR).
Leading healthcare fund manager, BioScience Managers, has moved into the rapidly growing anti-infectives market with a US$1m investment into Bulletin Board-listed AmpliPhi Biosciences Corporation (APHB.PK).
Read more about BioScience Managers Banks on Growth in Anti-Infectives Market
International life sciences investment group and major shareholder of Bioxyne, today backed the Bioxyne Board in their decision to withdraw from the company’s proposed transaction with Vitality Devices (See the announcement here).
Read more about Bioscience Managers Supports Bioxyne Decision on Transaction
A LEADING Australasian healthcare fund has generated a unit price of $1.81 for every dollar invested four and a half years ago, prompting its managers to urge superannuation funds to ‘strongly’ consider backing proven managers in the healthcare sector to secure better returns for their members.
(Melbourne) Leading Asia Pacific healthcare fund manager, BioScience Managers Pty Ltd, today announced a $3m investment in innovative New Zealand asthma technology company Nexus6.